Sun, X., Jiao, X., Ma, Y., Liu, Y., Zhang, L., He, Y., & Chen, Y
Try the BMI Calculator Dual-receptor weight loss: GIP and GLP-1 activation together produce 20%+ weight loss that doesn't depend on thyroid metabolic rate Visceral fat reduction: Targets the inflammatory abdominal fat that's disproportionately improved in hypothyroid patients Inflammation suppression: 30% to 40% reduction in CRP may ease systemic autoimmune symptoms Insulin resistance correction: Restores glucose metabolism toward normal ranges, achieving weight loss that was previously blocked Cardiovascular risk reduction: Improves lipid profiles, blood pressure, and metabolic markers that are commonly improved in Hashimoto's Important Safety Information Thyroid C-Cell Warning Like all GLP-1 receptor agonists, Zepbound carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma, or MTC) found in animal studies
TRACK SIDE EFFECTS IN CONTEXT Log how you feel and rate symptom severity
Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men
Not for use during pregnancy or breast-feeding